18585971

Source:http://linkedlifedata.com/resource/pubmed/id/18585971

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0087111, umls-concept:C0205466, umls-concept:C0209738, umls-concept:C0301625, umls-concept:C0369332, umls-concept:C0681842, umls-concept:C0871261, umls-concept:C0982327, umls-concept:C1704632, umls-concept:C1706817, umls-concept:C2911692
pubmed:issue	9
pubmed:dateCreated	2008-9-8
pubmed:abstractText	We aimed to investigate the early on-treatment HBV DNA response to predict sustained virologic response for peginterferon and lamivudine combination therapy.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101160775
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents, http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral, http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B e Antigens, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Lamivudine, http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b, http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2b
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	1542-7714
pubmed:author	pubmed-author:ChanHenry Lik-YuenHL, pubmed-author:ChanHoi-YunHY, pubmed-author:ChimAngel Mei-LingAM, pubmed-author:SungJoseph Jao-YiuJJ, pubmed-author:WongGrace Lai-HungGL, pubmed-author:WongVincent Wai-SunVW
pubmed:issnType	Electronic
pubmed:volume	6
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1022-6
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:18585971-Adult, pubmed-meshheading:18585971-Antiviral Agents, pubmed-meshheading:18585971-DNA, Viral, pubmed-meshheading:18585971-Drug Therapy, Combination, pubmed-meshheading:18585971-Female, pubmed-meshheading:18585971-Hepatitis B, pubmed-meshheading:18585971-Hepatitis B e Antigens, pubmed-meshheading:18585971-Hepatitis B virus, pubmed-meshheading:18585971-Humans, pubmed-meshheading:18585971-Interferon-alpha, pubmed-meshheading:18585971-Lamivudine, pubmed-meshheading:18585971-Male, pubmed-meshheading:18585971-Polyethylene Glycols, pubmed-meshheading:18585971-Predictive Value of Tests, pubmed-meshheading:18585971-Prognosis, pubmed-meshheading:18585971-ROC Curve, pubmed-meshheading:18585971-Recombinant Proteins, pubmed-meshheading:18585971-Sensitivity and Specificity, pubmed-meshheading:18585971-Time Factors, pubmed-meshheading:18585971-Treatment Outcome
pubmed:year	2008
pubmed:articleTitle	Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment.
pubmed:affiliation	Department of Medicine and Therapeutics and Institute of Digestive Disease, Chinese University of Hong Kong, Hong Kong SAR, China. hlychan@hotmail.com
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't